Protagenic Therapeutics, Inc.\new
PTIX · OTCMCIK 1022899fmd_1D904NPW35EMFX11CAE4VSM5MRManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2026, 58 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 0 | 0 | 0 | 0 | – | 0 | 0 |
| Net interest income | – | – | – | – | – | – | – | – | (1) | (1) |
| Research and development | 1 | 1 | 1 | 1 | 1 | 2 | 3 | – | 0 | 1 |
| Total operating expenses | 2 | 2 | 2 | 3 | 4 | 4 | 5 | – | 3 | 5 |
| Operating income | (2) | (2) | (2) | (3) | (4) | (4) | (5) | – | (3) | (5) |
| Interest expense | – | – | – | 0 | 0 | 0 | 0 | – | – | – |
| Interest and investment income | – | – | – | 0 | 0 | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | 0 | (0) | 0 | 0 | (0) | 0 | (0) | – | (1) | 6 |
| Income before taxes | (2) | (3) | (2) | (3) | (5) | (4) | (5) | (6) | – | 1 |
| Income tax expense | – | – | – | – | – | – | – | – | – | – |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (2) | (3) | (2) | (3) | (5) | (4) | (5) | – | (4) | 1 |